arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Matinas BioPharma Holdings, Inc.

MTNB

$0.18 0.00 (+1.49%) at close

14 Visible periods

24 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Matinas BioPharma Holdings, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —

Dividend Yield —

Revenue Growth None

Op. Margin —

ROIC -113.8% ↗

FCF / Share $-1.28 ↗

Trailing P/E —

Price / Book 0.2x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 23, 2026.

14-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$1.10M

↓ -65.6% —

Net Income Profit after all expenses

$-10.35M

↑ +57.3% —

FCF / Share Free cash flow per share

$-1.28

↑ +60.8% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality →

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗
Revenue Growth YoY (%)	—	—	-65.6% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-920%)	9560.6% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+119408%)	-79.2% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1089%)	76.3% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+854%)	-25.0% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-413%)	-20.0% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-350%)	—	N/M	—	—	—	—
EPS Growth YoY (%)	59.8% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	5.7% Fair ↑ Fair Improving Year-over-year change in earnings per share Optimal: > 10%	-5180.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	9.1% Fair Fair Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—	—	—	—
Net Income Growth YoY (%)	57.3% Excellent ↑ Excellent Improving Year-over-year change in net income	-5.7% Weak ↓ Weak Declining Year-over-year change in net income	-9.3% Weak ↓ Weak Declining Year-over-year change in net income	9.8% Fair ↑ Fair Improving Year-over-year change in net income	-3.7% Weak ↑ Weak Improving Year-over-year change in net income	-29.2% Weak ↑ Weak Improving Year-over-year change in net income	-23.4% Weak ↑ Weak Improving Year-over-year change in net income	9.1% Fair ↑ Fair Improving Year-over-year change in net income	-103.8% Weak ↓ Weak Declining Year-over-year change in net income	16.8% Good ↑ Good Improving Year-over-year change in net income	10.6% Fair Fair Year-over-year change in net income	-175.3% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	60.8% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	8.5% Fair ↑ Fair Improving Year-over-year change in free cash flow	-3756.7% Weak Weak Year-over-year change in free cash flow	-25.5% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—	—	—	—	—
Revenue CAGR 3Y (%)	—	—	90.6% Excellent ↑ Excellent Improving Compound annual revenue growth over 3 years	228.6% Excellent ↑ Excellent Improving Compound annual revenue growth over 3 years	-34.9% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	1.9% Weak Weak Compound annual revenue growth over 3 years	—	-14.9% Weak Weak Compound annual revenue growth over 3 years	—	—	—	—	—	—
Revenue CAGR 5Y (%)	—	—	55.7% Excellent ↑ Excellent Improving Compound annual revenue growth over 5 years	84.4% Excellent Excellent Compound annual revenue growth over 5 years	—	-4.0% Weak Weak Compound annual revenue growth over 5 years	—	—	—	—	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗
Effective Tax Rate (%) (%)	—	0.3% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	—	—	—	—	—	—	—	—
FCF / Net Income (x)	0.68x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.66x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.68x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.95x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.66x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.77x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.83x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.77x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.80x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗
Return on Invested Capital (%)	-113.8% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-323.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-97.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-53.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-37.2% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-30.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-45.2% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-71.7% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-122.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-91.2% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-128.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-371.1% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-28.0% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-96.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-194.5% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-94.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-54.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-40.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-34.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-47.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-73.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-114.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-84.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-117.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-311.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	-32.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-214.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1528%)	—	-119.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-895%)	-57.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-482%)	-44.4% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-396%)	-35.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-335%)	-52.6% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-450%)	-87.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-682%)	-145.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1067%)	-106.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-809%)	-150.4% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1103%)	—	-35.4% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-336%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗
Net Debt (USD)	$-4.00M	$-7.28M	$-4.79M	$-6.83M	$-21.03M	$-12.43M	$-22.17M	$-12.45M	$-7.31M	$-4.11M	$-3.23M	$-2.59M	$-10.84M	$-424.36K

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗
Revenue per Share (USD)	—	—	$0.25	$0.01	$0.00	—	—	—	—	—	—	—	—	—
Basic EPS, GAAP (USD)	$-2.00	$-4.98	$-5.28	$-0.10	$-0.11	—	—	—	—	—	—	—	—	—
Free Cash Flow per Share (USD)	$-1.28	$-3.26	$-3.57	$-0.09	$-0.07	—	—	—	—	—	—	—	—	—
Book Value per Share (USD)	$0.75	$1.49	$4.43	$0.17	$0.24	$0.32	$0.20	$0.14	$0.11	$0.12	$0.11	$0.07	$0.33	—
Tangible Book Value per Share (USD)	$0.40	$1.05	$3.43	$0.15	$0.22	$0.30	$0.19	$0.13	$0.10	$0.10	$0.08	$0.07	$0.33	—
Basic Weighted Avg Shares (shares)	5.47M	4.87M	4.35M	216.81M	210.18M	—	—	—	—	—	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗
Working Capital (USD)	$2.61M	$5.36M	$12.92M	$30.25M	$46.65M	$57.99M	$26.83M	$10.25M	$6.19M	$3.12M	$2.43M	$1.69M	$10.07M	—
Total Equity (USD)	$4.83M	$7.59M	$19.25M	$36.64M	$52.49M	$63.73M	$33.05M	$16.14M	$10.68M	$7.15M	$6.07M	$2.23M	$10.47M	$-116.59K

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗	FY 2012 Dec 31, 2012 10-K ↗
Sales/Revenue/Turnover (USD)	—	—	$1.10M	$3.19M	$33.00K	$158.33K	$89.81K	$119.75K	$149.69K	$0.00	$194.49K	$0.00	—	—
Depreciation Expense (USD)	$32.00K	$365.00K	$385.00K	$337.00K	$244.00K	$231.06K	$205.96K	$218.31K	$100.61K	$52.64K	$43.50K	$41.58K	$1.13K	—
Net Income, GAAP (USD)	$-10.35M	$-24.25M	$-22.94M	$-21.00M	$-23.28M	$-22.45M	$-17.37M	$-14.08M	$-15.49M	$-7.60M	$-9.14M	$-10.22M	$-3.71M	—
Operating Cash Flow (USD)	$-7.01M	$-15.88M	$-15.28M	$-19.16M	$-15.22M	$-17.37M	$-14.09M	$-10.32M	$-11.46M	—	—	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 14 years · 56 quarters

Matinas BioPharma Holdings, Inc.

Analytical Summary

14-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare MTNB with peers